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tissue products and how this applies to cord blood
units. She indicated that peripheral blood stem cells
and cord blood are regulated as biologic cell therapies
under the tissue approach. Implementation of the reg-
ulatory approach is under way, and a period of en-
forcement discretion for unrelated donor cord blood
is ongoing. Cord blood manufacturers currently must
register with the Food and Drug Administration. Fi-
nalizing regulations is currently a Food and Drug
Administration priority. There is a recognized need
for international harmonization of cord blood regula-
tions.
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CORD BLOOD TRANSPLANTATION TO ADULT PATIENTS: A SINGLE-
BANK’S EXPERIENCE
Stevens, C.E., Scaradavou, A., Rubinstein, P. National Cord Blood Pro-
gram of the New York Blood Center
Since 1993, the New York Blood Center has provided cord blood
(CB) grafts to more than 1500 recipients, 421 of whom where adults
(age 16). These patients were treated in 53 US and 26 non-US
Transplant Centers (TCs). Data from 391 (92.9%) are available.
The proportion of adult recipients has grown from 9% in 1995 to
over 30% in 2001-2003. More than 90% (363/391) had leukemia
(41% advanced), lymphoma, or myelodysplasia. No. of patients
aged 16-24, 25-39, and 40: 130, 135, and 125, respectively; there
were 15% African American recipients, 13.3%Hispanic, and 65.6%
Caucasoids, respectively. TNC doses 2.5  107/kg were given to
62%, 25-49  107/kg to 37%, and 5  107/kg to 1.3% of all
recipients. HLA was matched at serological levels for A and B and
at DNA allele level for HLA-DR. Seven TCs have performed 10
CB transplantations each. Neutrophil engraftment was signiﬁcantly
reduced when TNC doses2.5 107/kg and stratiﬁed signiﬁcantly
with HLA mismatch levels. Engraftment was superior with TBI
conditioning compared to no TBI; and regimens including meth-
otrexate associated with reduced engraftment. Overall survival was
30.2% at one year and 23% at ﬁve years post-transplant. Centers
with 10 CB transplantations had better survival (by Cox Regres-
sion analysis) and so did those with better HLA matches, those
without advanced stage leukemia, and those whose conditioning
included ﬂudarabine. The effect of cell dose was not signiﬁcant in
the Cox regression. Patients with good HLA matches (6/6 and 5/6
without rejection mismatches) and those conditioned with regimens
including TBI and ﬂudarabine had excellent survival: 68% at one
year, respectively.
The data indicate that, despite the low graft cell doses, remarkable
improvement in overall survival rate of adults transplanted with
cord blood is possible by improvements in HLA matching and
conditioning regimens.
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UMBILICAL CORD BLOOD TRANSPLANTATION: NOVEL APPROACHES
TOWARD IMPROVING ENGRAFTMENT
Wagner, J.E., Barker, J. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable donors,
reducing the risks of acute and chronic graft-versus-host disease
(GVHD) and improving survival. Cell dose, however, has clearly
been identiﬁed as a major limitation, often preventing the consid-
eration of UCB for adult recipients. Recipients of 1.7 
105CD34/kg have slow hematopoietic recovery (median 35 days)
and signiﬁcantly lower incidence of engraftment (68% [95% CI,
46-91]). Therefore, strategies for increasing the cell dose, e.g., ex
vivo HSC expansion, transplantation of multiple UCB units, and
co-infusion of healthy haploidentical mesenchymal stem cells
(MSC), are being explored.
Multi-unit UCB transplantation. Twenty-three adult and adoles-
cent patients [median age 24 years (range: 13-53)] with high-risk
hematologic malignancy were transplanted with two partially HLA-
matched UCB units after myeloablative conditioning. The median
total infused dose 3.5  107NC/kg (range 1.1-6.3). All evaluable
patients (n  21) engrafted at a median of 23 days (range 15-41)
with one unit predominating. While there was no association be-
tween nucleated cell dose, CD34 cell dose, or HLA-A,B,DRB1
match and which unit predominated, the winning unit had a higher
CD3 dose. Incidence of severe III-IV acute graft-versus-host
disease (GVHD) was 13% (0-26%), and disease-free survival was
57% (95% CI: 35-79) at 1 year. These data suggest that 1) double
unit UCBT is safe with one unit predominating over time, 2) the
unit that disappears over time may facilitate engraftment of the
winning unit, possibly by immune mediated mechanisms, and 3)
CD3 dose might predict which unit will ultimately engraft long
term. Most importantly, the use of two UCB units extends the
application of this treatment to nearly all adults for whom one unit
would have been insufﬁcient.
Co-Infusion of haploidentical MSC and UCB transplantation. Fifteen
patients [median age 7.5 years (range: 0.2-16)] with high risk leu-
kemia were transplanted with HLA 0-2 antigen mismatched UCB
and haploidentical parental donor MSC after a myeloablative con-
ditioning. No toxicity was observed related to the infusion of MSC.
All treated patients (n  8) had hematopoietic recovery and com-
plete chimerism at a median of 19 days (range: 9-28). Platelet
recovery occurred at a median of 1.7 months (range: 1.2-3.3).
Incidence of grade II-IV acute GVHD was 2 of 8 patients with no
patient having chronic disease. With a median followup of 2.9 years,
6 patients are alive and disease free with two patients dying of
infections on days 53 and 63, respectively. These data suggest that
engraftment, particularly platelet recovery, may be enhanced by the
co-infusion of MSC. Clearly larger patient numbers are required to
conﬁrm these preliminary observations.
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UMBILICAL CORD BLOOD TRANSPLANTATION AFTER A NON-MYELOA-
BLATIVE THERAPY IN HIGH RISK ADULTS
Wagner, J.E., Barker, J. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Bone marrow transplantation (BMT) in adults is associated with a
high risk of graft-versus-host disease (GVHD), opportunistic infec-
tion and regimen related toxicity. For these reasons, umbilical cord
blood (UCB) after a non myeloablative preparative regimen has
been explored.
Fifty-one adults with advanced hematologic malignancies [median
age 50 years (range 19-60)], ineligible for myeloablative condition-
ing by virtue of advanced age, extensive prior therapy or serious
co-morbidities received UCB transplantation after cyclophospha-
mide 50 mg/kg, ﬂudarabine 200 mg/m2, and 200 cGy TBI. Immu-
nosuppression was with cyclosporine-A to at least day 100 and
mycophenolate mofetil to day 30. Eight patients with no combina-
tion chemotherapy in the 6 months prior to transplant also received
ATG during conditioning. Thirteen patients (25%) received single
UCB units and 38 (75%) received double unit grafts. The median
total infused cell dose was 3.4  107NC/kg (range 1.1-5.7). Units
were predominantly 1-2 antigen HLA mismatched with the recip-
ient. Of 50 evaluable patients, neutrophil recovery occurred at a
median of 8 days (range 5-32). Four patients had failure of donor
derived engraftment with autologous recovery and 1 had late graft
rejection. The cumulative incidence of sustained donor engraftment
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